Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Indium-111 is a radioactive isotope (^111^In) that decays by electron capture with a half-life of approximately 2.8 days (67–68 hours). During decay, it emits gamma photons (171.3 and 245.4 keV) that serve as the basis for diagnostic imaging procedures in nuclear medicine. Indium-111 can be used to label monoclonal antibodies, white blood cells, platelets, or small molecules, allowing targeted imaging of cancers, infections, inflammation, and certain neurologic indications. Indium-111 and its gamma photon emissions are critical for nuclear imaging but are not themselves molecular targets; rather, they are tools employed to visualize the distribution and trafficking of radiolabeled compounds or cells.
Decay by electron capture — resulting in emission of gamma photons (171 and 245 keV) which can be detected by gamma cameras (planar or SPECT)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma photon emission from indium‑111 (^111^In or In-111).